A review of the provided information does not yield details regarding US patent 5,753,501 specifically in relation to the biosynthesis of acarbose.
What is Acarbose Used For?
Acarbose is a medication used to treat type 2 diabetes by helping to control blood sugar levels after meals [1]. It works by inhibiting alpha-glucosidase enzymes in the digestive system, which slows down the breakdown of complex carbohydrates into glucose [1].
How Does Acarbose Work?
As an alpha-glucosidase inhibitor, acarbose interferes with the enzymatic digestion of disaccharides and oligosaccharides in the small intestine [1]. This mechanism delays glucose absorption, leading to a reduced postprandial (after meal) rise in blood glucose [1].
When Does the Patent for Acarbose Expire?
Information regarding the specific patent expiry for US patent 5,753,501 is not available in the provided context. Patent expiration dates are crucial for understanding when generic versions of a drug can enter the market. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals [2].
Who Manufactures Acarbose?
Multiple pharmaceutical companies manufacture and market acarbose. Brand names include Precose and Glucobay, and generic versions are also widely available [1].
What are the Side Effects of Acarbose?
Common side effects associated with acarbose include gastrointestinal issues such as diarrhea, abdominal pain, and flatulence [1]. These effects are often related to the undigested carbohydrates reaching the colon [1].
What are the Risks of Taking Acarbose?
Beyond common side effects, potential risks include rare instances of liver enzyme elevations [1]. Patients with certain pre-existing conditions, such as inflammatory bowel disease, should use acarbose with caution [1].
How Does Acarbose Compare to Other Diabetes Medications?
Acarbose is a member of the alpha-glucosidase inhibitor class, distinct from other diabetes medications like metformin (a biguanide) or sulfonylureas [1]. Its mechanism of action is specific to carbohydrate digestion and absorption, offering a different approach to glycemic control [1].
Can Biosimilars or Generics Be Made Before Patent Expiry?
Generally, generic or biosimilar versions of a drug cannot be legally marketed in the United States until the relevant patents and any periods of market exclusivity have expired [3]. This protects the innovation of the original drug developer [3].
What is the Clinical Data on Acarbose?
Clinical trials have demonstrated acarbose's efficacy in lowering postprandial blood glucose levels and glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes [1]. Its cardiovascular benefits are a subject of ongoing research and discussion within the medical community [1].
What is the Regulatory Status of Acarbose?
Acarbose has been approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the management of type 2 diabetes [1].
---
Sources:
[1] https://www.nps.org.au/australian-medicines-handbook/medicines/acarbose
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cdER/patent-term-restoration